Corsair Pharma's transdermal patch delivered stable treprostinil levels over 24 hours with minimal fluctuation in early human trials, demonstrating pharmacokinetic performance comparable to injectable alternatives. This delivery method addresses a significant clinical gap in pulmonary hypertension treatment by reducing dosing frequency and injection burden while maintaining therapeutic consistency.
Key Points
- Steady 24-hour plasma levels with low peak-to-trough variation achieved
- Transdermal delivery matches subcutaneous pharmacokinetics without daily injections
- Acceptable safety profile supports advancement to larger clinical trials
Longevity Analysis
Pulmonary hypertension accelerates cardiovascular decline and impairs oxygen delivery across multiple organ systems. Stabilizing drug levels across 24 hours reduces the physiological stress of plasma fluctuations that trigger compensatory activation of the stress response system—a mechanism that itself drives endothelial dysfunction and accelerates vascular aging. Transdermal delivery eliminates the burden of frequent injections, improving treatment adherence and reducing the cumulative inflammatory stimulus from repeated needle trauma. For patients managing chronic vasodilatory therapy, steady-state exposure represents a meaningful shift toward sustained systemic stability rather than the cyclical peaks and troughs that characterize current regimens.
Original published by Longevity.Technology.